title: Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
abstract: Subgroups of the B cell malignancies are known to be associated with Epstein-Barr virus (EBV) infection, especially in immunocompromised patients. These are fatal and refractory to conventional antineoplastic therapy. B cells are usually post-mitotic cells and even mitogen activated or transformed B cells have shown relative resistance against viral mediated gene transfer. To address this issue, we employed a replication-defective herpes simplex virus-1 (HSV-1) to mediate gene transfer into EBV-transformed B cells. The virus expresses the herpes simplex virus thymidine kinase (HSV-TK) and the E. coli lacZ reporter genes and is designated T0Z.1. We used the lymphoblastoid cell line SWEIG as a model for human EBV-related B cell malignancy. This cell line was established by in vitro EBV infection of primary human peripheral blood mononuclear cells. When SWEIG cells were infected with T0Z.1, X-gal staining revealed lacZ expression in more than 20% cells even at multiplicity of infection (MOI) as low as 1 and the expression persisted for at least one week. Ganciclovir (GCV) administration after T0Z.1 infection effectively decreased the number of the infected tumor cells in a dose-responsive manner. Viral toxicity was analyzed by cell proliferation assay (MTS assay) and found to be little even at 10 MOI infection. Three MOI of the virus yielded maximum antineoplastic effect and more than 50% tumor cells were killed by HSV-TK/GCV. These results suggest the potential utility of replication-defective HSV-1 for the treatment of EBV-related B cell malignancies.
authors.affiliation: Gene Therapy Program, University of Alabama at Birmingham, Alabama, 35294-3000, USA.
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: A
authors.initials: A
authors.lastname: Piche
authors.forename: K
authors.initials: K
authors.lastname: Kasono
authors.forename: J
authors.initials: J
authors.lastname: Xiang
authors.forename: J
authors.initials: J
authors.lastname: Gomez-Navarro
authors.forename: S
authors.initials: S
authors.lastname: Moriuchi
authors.forename: D M
authors.initials: DM
authors.lastname: Krisky
authors.forename: T
authors.initials: T
authors.lastname: Oligino
authors.forename: J C
authors.initials: JC
authors.lastname: Glorioso
authors.forename: T J
authors.initials: TJ
authors.lastname: Curiel
authors.forename: D T
authors.initials: DT
authors.lastname: Curiel
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000821:virology*; D002455:Cell Division / Q000187:drug effects; D002472:Cell Transformation, Viral; D004305:Dose-Response Relationship, Drug; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D018259:Herpesvirus 1, Human / Q000201:enzymology / Q000235:genetics* / Q000502:physiology; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000472:pathogenicity; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy* / Q000821:virology; D013937:Thymidine Kinase / Q000235:genetics*; D014779:Virus Replication / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D013937:Thymidine Kinase; D015774:Ganciclovir